Topics

NICE backs Cancer Drugs Fund use of Rubraca in ovarian cancer after Clovis amends price https://www.firstwordpharma.com/node/1673378  $CLVS

07:38 EDT 11 Oct 2019 | FirstWord Pharma

NICE backs Cancer Drugs Fund use of Rubraca in ovarian cancer after Clovis amends price https://www.firstwordpharma.com/node/1673378 

Original Article: NICE backs Cancer Drugs Fund use of Rubraca in ovarian cancer after Clovis amends price https://www.firstwordpharma.com/node/1673378  $CLVS

NEXT ARTICLE

More From BioPortfolio on "NICE backs Cancer Drugs Fund use of Rubraca in ovarian cancer after Clovis amends price https://www.firstwordpharma.com/node/1673378  $CLVS"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...